Cargando…

Reply to comments and questions of Dr. Correale et al. about our review concerning CTEPH

Detalles Bibliográficos
Autores principales:	Schölzel, Bastiaan E., Snijder, Repke J., Mager, Johannes J., van Es, Hendrik W., Plokker, Herbert W.M., Reesink, Herre J., Morshuis, Wim J., Post, Martijn C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2015
Materias:	Letter-to-the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352150/ https://www.ncbi.nlm.nih.gov/pubmed/25884088 http://dx.doi.org/10.1007/s12471-015-0668-7

Ejemplares similares

Chronic thromboembolic pulmonary hypertension
por: Schölzel, B. E., et al.
Publicado: (2014)

Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology
por: Bofarid, Sala, et al.
Publicado: (2021)

Response to ‘Pulmonary arterial hypertension: An update’ by M. Correale (10.1007/s12471-012-0245-2)
por: Hoendermis, E. S.
Publicado: (2012)

Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence
por: de Gussem, Els M., et al.
Publicado: (2020)

Comparison of Contrast Enhanced Magnetic Resonance Angiography to Computed Tomography in Detecting Pulmonary Arteriovenous Malformations
por: van den Heuvel, Daniel A.F., et al.
Publicado: (2020)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

NOVEL CTEPH MIMICKERS IN THE COVID-19 ERA
por: Pietrowicz, Rylie, et al.
Publicado: (2022)

Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia
por: Vorselaars, Veronique M. M., et al.
Publicado: (2018)

Central versus Peripheral CTEPH—Clinical and Hemodynamic Specifications
por: Kaldararova, Monika, et al.
Publicado: (2022)

Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2020)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
por: Jansa, Pavel, et al.
Publicado: (2022)

Correction: Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism
por: Boon, Gudula J. A. M., et al.
Publicado: (2020)

Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study
por: Hessels, Josefien, et al.
Publicado: (2022)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Cardiopulmonary exercise testing and pulmonary function testing for predicting the severity of CTEPH
por: Zhu, Hanqing, et al.
Publicado: (2021)

Pulmonary artery sarcoma presenting as chronic thromboembolic pulmonary hypertension (CTEPH)
por: Ampatzidou, Fotini, et al.
Publicado: (2023)

Our Reply
Publicado: (1881)

The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression
por: Smolders, Valérie F. E. D., et al.
Publicado: (2021)

Replies to the physics question
por: CERN. Geneva
Publicado: (1995)

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014)

Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study
por: Yang, Suqiao, et al.
Publicado: (2021)

Variation of PetCO(2) during incremental exercise and severity of IPAH and CTEPH
por: Sun, Xingxing, et al.
Publicado: (2022)

Reply to "The LEPC general question on particle identification"
por: Pilcher, J E
Publicado: (1982)

Reply to: ‘NAFLD or comorbidities, that is the question’
por: Ji, Dong, et al.
Publicado: (2020)

The Woman Question: A Reply
por: Sheldon, D. L. D.
Publicado: (1873)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
por: Andersen, Asger, et al.
Publicado: (2017)

Elevated lipoprotein A in acute on chronic CTEPH with cardiogenic shock: a case report
por: Kyaw, Kyaw, et al.
Publicado: (2021)

Inherited Thrombophilia in Chinese CTEPH Patients: A Rather Common Finding in an Uncommon Condition
por: Kearney, Katherine, et al.
Publicado: (2022)

Our Position on the Vivisection Question
Publicado: (1898)

Our Position on the Gold Question
por: Taft,, et al.
Publicado: (1855)

Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH
por: Kriechbaum, Steffen D., et al.
Publicado: (2020)

Reply: The tools of our trade
por: Dhawan, Richa
Publicado: (2021)

ANA Negative Systemic Lupus Erythematosus Leading to CTEPH, TTP-Like Thrombocytopenia, and Skin Ulcers
por: Changal, Khalid Hamid, et al.
Publicado: (2016)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
por: Sharma, Munish, et al.
Publicado: (2021)

Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry
por: Guth, Stefan, et al.
Publicado: (2021)

Balloon pulmonary angioplasty in the current era of CTEPH treatment: How did we get here?
por: Yang, Jenny Z., et al.
Publicado: (2023)

QUESTIONS & REPLIES FOLLOWING THE PUBLIC MEETING
por: Staff Association
Publicado: (2022)

Questioned Virginity Has No Definite Reply
por: Zayed, Abeer Ahmed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f3v497q9p79ln4dm5l7dj2gvph